Tempus AI is gaining momentum with a unique business model and recent technology validation through the Personalis acquisition. Its diagnostics and data segments grew 19.4% year-over-year in Q2 2026, supported by major partnerships and an expanding proprietary database. Upcoming FDA approvals, expanded test offerings, and pricing increases are expected to boost revenue and margins significantly from 2027 onward. Despite risks from dilution and debt, the company targets positive free cash flow by the end of 2026, backed by strong management and a solid balance sheet.
Tempus AI, Inc. has acquired Personalis' cancer monitoring tests to enhance its AI-driven precision medicine platform. This move aligns with recent cancer vaccine progress by Merck and Moderna, highlighting the strategic growth potential for Tempus. ...
Tempus AI agreed to acquire Personalis for $1.5 billion in a stock deal, gaining access to Personalis's ultrasensitive cancer DNA detection test, NeXT Personal. This technology supports a personalized mRNA cancer vaccine by Moderna and Merck, which r...
Tempus AI reported its first GAAP profit driven by growth in its data business and improved operating leverage from oncology volume and high-margin products. The company raised its 2026 revenue guidance to $1.595–$1.605 billion, a 25% increase year-o...
